![]() |
New to the Huntington's
Disease Lighthouse? |
||
| |
| |
| |
| |
| |
| |
| |
||
Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study.N.Z. Hobbs, J. Barnes, C. Frost, S.M.D. Henley, E.J. Wild, K. Macdonald, R.A. Barker, R.I. Scahill, N.C. Fox and S.J. Tabrizi press release: Background AND Purpose: Longitudinal MR imaging measures provide an opportunity to track progression in HD before the emergence of clinical symptoms. This may prove useful in assessing disease-modifying treatments. We investigated how caudate and global volumes change as HD progresses from premanifest to early disease. Materials and Methods: Forty HD gene-positive individuals and 19 controls underwent serial volumetric MR imaging (baseline, 12 and 27 months; 2 or 3 scans per person). At baseline, 3 patients with HD were premanifest but developed overt motor features during the study, and 37 had early HD. All had dates of motor onset recorded. Caudates, lateral ventricles, and TIVs were measured using semiautomated procedures. Linear mixed models were used to investigate differences between HD and controls in relation to motor onset, controlling for TIV, sex, and age. Results: Extrapolating backwards in time, we found that differences in caudate and ventricular volumes between patients with HD and controls were evident 14 and 5 years, respectively, before motor onset (P +/- .05). At onset, caudate volume was 2.58 mL smaller than that in controls (P +/- .0001); ventricular volume was 9.27 mL larger (P +/- .0001). HD caudate atrophy rates were linear, showed low variability between subjects, and were approximately 10-fold higher than those in controls (P +/- .001). HD ventricular enlargement rates were variable between subjects, were approximately 4-fold higher than those in controls at onset (P +/- .001), and accelerated with disease duration (P = .02). Conclusions: We provide evidence of acceleration of global atrophy in HD with disproportionate caudate involvement. Both caudate and global measures may be of use as early markers of HD pathology. Source: American Journal of Neurradiology 2010 Feb 11. [Epub ahead of print]
|
Research focusing on the formation of aggregates caused by HD
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
Learn more about the clinical trial process, trials that have been conducted and those that are underway.
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
Research focusing on gene therapy.
Research focusing on gene transcription.
General research related to HD
Research studying the genetics of Huntington's Disease
Research studying the Immune System and it's effect on the progression of HD
Research studying the brain tissue and research related to stem cells
26 Sep 2007
Press release for the BDNF neurogenesis study.
25 Aug 2007
Gene Expression Analysis and Extra-Mitochondrial Energy Metabolism
The HD protein causes a depletion in cellular energy but not through direct effects on the mitochondria, the cell's energy factory.
24 Aug 2007
RE1/NRSE Mediated Gene Transcription
Exciting research suggests that restoring the expression of the genes that the HD protein suppresses could be a major treatment.
20 Aug 2007
The Molecular Zip Code Research Yields a Drug Target
The molecular zip code research suggests that a kinase inhibitor could be a major treatment for Huntington
19 May 2007
D1 receptors and HD
Researchers generated a mouse which progressively lost Dopamine 1 receptor cells and got Huntington's Disease like symptoms.
1 Apr 2007
Copper in the HD brain
Researchers have discovered that excess copper plays a role in Huntington's Disease pathology.
13 Feb 2007
Molecular Zipcodes Provide Address for HD Protein
New findings based on new technology show that the HD protein is being misdirected within the cell. Small molecules are being developed which might place a 'molecular zip code' on the problem.
6 Feb 2007
NCAMs in the HD mice
Problems with NCAMs may explain cognitive and olfactory dysfunction in HD.
19 Dec 2006
Stem Cells and The Aging Brain
Stem cells are still present in the middle aged brain; they just aren't dividing.
8 Dec 2006
ReNeuron Files Application with FDA to Begin Phase I Study of Stem Cell Treatment for Stroke Patients.
A company currently doing stem cell research in animal models of HD, has filed an application with the FDA for permission to begin clinical trials of stem cell treatments for stroke victims.
All Updates for The Brain |
|||||||||||||||||
| Disclaimer &
Privacy Policy | |
|